A First-in-Human Study of CD123 Natural Killer Cell Engager (NKCE) SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS)

被引：0

作者：

Stein, Anthony ^{[1
]}

Lavrencic, Mojca ^{[2
]}

Garciaz, Sylvain ^{[3
]}

Huls, Gerwin ^{[4
]}

Maiti, Abhishek ^{[5
]}

Boissel, Nicolas ^{[6
]}

Botton, Stephane ^{[7
]}

Fleming, Shaun ^{[8
]}

Zwaan, Michel ^{[9
]}

de Leeuw, David C. ^{[10
]}

Desai, Pinkal ^{[11
]}

Arellano, Martha ^{[12
]}

Avigan, David ^{[13
]}

Langemeijer, Saskia ^{[14
]}

Jensen, Kyle ^{[15
]}

Wagenaar, Timothy ^{[15
]}

Mi Gu ^{[15
]}

Abbadessa, Giovanni ^{[15
]}

Bajel, Ashish ^{[16
,17
]}

机构：

[1] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[2] Erasmus Univ, Med Ctr, Rotterdam, Netherlands

[3] Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France

[4] Univ Med Ctr Groningen, Groningen, Netherlands

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Hop St Louis, Paris, France

[7] Inst Gustave Roussy, Paris, France

[8] Alfred Hlth, Melbourne, Vic, Australia

[9] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

[10] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[11] Weill Cornell Med, New York, NY USA

[12] Emory Univ, Atlanta, GA 30322 USA

[13] Beth Israel Deaconess Med Ctr, Boston, MA USA

[14] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[15] Sanofi, Cambridge, MA USA

[16] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[17] Royal Melbourne Hosp, Melbourne, Vic, Australia

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-002

引用

页码：S3 / S4

页数：2

共 50 条

[21] Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Zhang, Xian
Yang, Junfang
Shi, Yanze
Song, Dan
Li, Jingjing
Lu, Xin-an
Wu, Fei
Li, Jianqiang
Chen, Dandan
Li, Xiangqun
Xu, Zhongwei
Liu, Shuqiang
Li, Ziyu
Ying, Kui
Wang, Wenya
Lu, Peihua
BLOOD, 2019, 134
[22] A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)
Davids, Matthew S.
Valero, Yesid Alvarado
Diefenbach, Catherine
Egan, Daniel N.
Dinner, Shira N.
Al Malki, Monzr M.
Begna, Kebede
Kallam, Avyakta
Abedin, Sameem
Cook, Rachel
Javidi-Sharifi, Nathalie
Dominguez, Edward
Miao, Lu
Ghalie, Richard G.
Danilov, Alexey
BLOOD, 2023, 142
[23] ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Maude, S. L.
Grupp, S. A.
Pulsipher, M. A.
Rives, S.
Myers, G. D.
Verneris, M. R.
Buechner, J.
Laetsch, T. W.
Bittencourt, H.
Boyer, M.
De Moerloose, B.
Qayed, M.
Davies, S.
Martin, P. L.
Bader, P.
Schlis, K.
Wood, P.
Taran, T.
Zhang, Y.
Leung, M.
June, C. H.
Levine, J.
HAEMATOLOGICA, 2017, 102 : 197 - 198
[24] A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults
Andrade, Aurelio Matos
Teixera, Vitoria Rodrigutes
Pogue, Robert
Figueiredo, Ana Claudia Morais Godoy
Carvalho, Juliana Lott
CYTOTHERAPY, 2023, 25 (09) : 930 - 938
[25] BUDGET IMPACT ANALYSIS ON BLINATUMOMAB FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R BCP-ALL)
Zhao, J.
Jin, G.
Yang, L.
VALUE IN HEALTH, 2022, 25 (07) : S404 - S405
[26] A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)
Zhang, Xian
Wang, Jiasheng
Liu, Yue
Yang, Junfang
Li, Jingjing
Zhang, Gailing
Shi, Yanze
He, Jiujiang
Song, Dan
Li, Wenqian
Xia, Shulian
Zhang, Min
Zhou, Zhixiao
Jia, Lemei
Zheng, Hongli
Lin, Xin
Lu, Peihua
BLOOD, 2020, 136
[27] Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Assi, Rita
Kantarjian, Hagop M.
Khouri, Rita
Ravandi, Farhad
Kebriaei, Partow
Short, Nicholas J.
Thomas, Deborah A.
Garcia-Manero, Guillermo
Champlin, Richard E.
Kadia, Tapan
Cortes, Jorge E.
Jain, Nitin
Konopleva, Marina
Estrov, Zeev
Takahashi, Koichi
Sasaki, Koji
Jacob, Jovitta
Manzoor, Ameena
Garris, Rebecca
O'Brien, Susan M.
Jabbour, Elias J.
BLOOD, 2017, 130
[28] Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
Sanchez, Pilar Martinez
Zugmaier, Gerhard
Gordon, Paul
Jabbour, Elias
Roca, Jose J. Rifon
Schwartz, Stefan
Borlenghi, Erika
Huguet, Francoise
Hernandez-Rivas, Jesus Maria
Lussana, Federico
Berthon, Celine
Kadu, Priti
Wong, Hansen
Markovic, Ana
Katlinskaya, Yuliya
Rambaldi, Alessandro
BLOOD, 2022, 140 : 6122 - 6124
[29] A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)
Bachier, Carlos
Borthakur, Gautam
Hosing, Chitra
Blum, William
Rotta, Marcello
Ojeras, Paulius
Barnett, Brian
Rajangam, Kanya
Majhail, Navneet S.
Nikiforow, Sarah
BLOOD, 2020, 136
[30] Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study
Roddie, Claire
Sandhu, Karamjeet S.
Tholouli, Eleni
Shaughnessy, Paul
Barba, Pere
Guerreiro, Manuel
Bishop, Michael R.
Yared, Jean A.
Ghobadi, Armin
Yallop, Deborah
Logan, Aaron C.
Beitinjaneh, Amer M.
Pantin, Jeremy M.
Arellano, Martha
Chaganti, Sridhar
Malladi, Ram
Menne, Tobias
Escamilla Gomez, Virginia
Hodby, Katharine
Gundabolu, Krishna
Mountjoy, Luke
O'Dwyer, Kristen M.
Abedin, Sameem
Alkhateeb, Hassan
Shah, Bijal D.
Lao-Sirieix, Pierre
Pittari, Gianfranco
Saxena, Kapil
Zhang, Yiyun
Brugger, Wolfram
Pule, Martin A.
Park, Jae H.
DeAngelo, Daniel J.
Jabbour, Elias
BLOOD, 2023, 142

← 1 2 3 4 5 →